The Desmoid Tumor Research Foundation

About DTRF

News & Updates

Stay Up to Date

Join The DTRF Newsletter

Join the Clinicians & Researchers Newsletter

OGSIVEO FDA-Approval Featured Image

Featured News

FDA APPROVES OGSIVEO™ (NIROGACESTAT), AS THE FIRST MEDICAL THERAPY FOR THE TREATMENT OF ADULTS WITH PROGRESSING DESMOID TUMORS.

Read More about FDA APPROVES OGSIVEO™ (NIROGACESTAT), AS THE FIRST MEDICAL THERAPY FOR THE TREATMENT OF ADULTS WITH PROGRESSING DESMOID TUMORS.

Filter by:

December 10, 2024

Update: OGSIVEO® (nirogacestat) Now Available in 150 mg and 100 mg Tablets

Read More about Update: OGSIVEO® (nirogacestat) Now Available in 150 mg and 100 mg Tablets

November 8, 2024

DTRF Hosts the 2024 “Together We Will” Weekend in Houston

Read More about DTRF Hosts the 2024 “Together We Will” Weekend in Houston

June 20, 2024

Updated Desmoid Tumor Treatment Guidelines, funded in part by DTRF, Published in JAMA Oncology

Read More about Updated Desmoid Tumor Treatment Guidelines, funded in part by DTRF, Published in JAMA Oncology

June 14, 2024

DTRF Executive Director Lynne Hernandez served as a faculty member this year at an educational session – 2024 Annual Meeting for the American Society of Clinical Oncology (ASCO)

Read More about DTRF Executive Director Lynne Hernandez served as a faculty member this year at an educational session – 2024 Annual Meeting for the American Society of Clinical Oncology (ASCO)

March 19, 2024

Young Adult Virtual Event Series: “Times Are A-Changin’: Heading into Young Adulthood with a Desmoid Tumor.”

Read More about Young Adult Virtual Event Series: “Times Are A-Changin’: Heading into Young Adulthood with a Desmoid Tumor.”

OGSIVEO FDA-Approval Featured Image

November 27, 2023

FDA APPROVES OGSIVEO™ (NIROGACESTAT), AS THE FIRST MEDICAL THERAPY FOR THE TREATMENT OF ADULTS WITH PROGRESSING DESMOID TUMORS.

Read More about FDA APPROVES OGSIVEO™ (NIROGACESTAT), AS THE FIRST MEDICAL THERAPY FOR THE TREATMENT OF ADULTS WITH PROGRESSING DESMOID TUMORS.